Full Breakdown
NHS Introduces Long-Acting Injectable HIV Prevention
10/17/2025, 9:15:01 PM
Introduction of Cabotegravir Injection
The National Institute for Health and Care Excellence (NICE) has approved the long-acting injectable HIV prevention treatment, cabotegravir (CAB-LA), for use on the NHS in England and Wales. This marks a significant advancement in HIV prevention strategies, aligning England and Wales with Scotland's existing policies. The injection, administered every two months, is designed for individuals at high risk of acquiring HIV who face challenges with daily oral pre-exposure prophylaxis (PrEP) tablets. Approximately 1,000 people annually are expected to benefit from this new option, which is set to be available at sexual health clinics across the country in the coming months.
Mechanism and Effectiveness
Cabotegravir works by blocking the integrase enzyme that HIV requires to replicate, effectively preventing the virus from establishing an infection. Studies indicate that when used correctly, the injection is nearly 100% effective at preventing HIV transmission. This new treatment provides a vital alternative for those unable to adhere to daily oral medications due to medical contraindications, difficulty swallowing pills, or personal circumstances such as homelessness or domestic violence.
Official Statements & Responses
Health Secretary Wes Streeting described the approval of cabotegravir as "game-changing," emphasizing its potential to provide hope for vulnerable populations unable to utilize other HIV prevention methods. He stated, "We’re making real progress on HIV, with PrEP use up by 8% this year, and our ambition goes even further." Dr. Michael Brady, National Advisor for LGBT+ Health at NHS England, highlighted the injection as a significant addition to HIV prevention strategies, ensuring that everyone who needs PrEP can access it.
Criticism & Opposition
While the introduction of cabotegravir has been largely welcomed, some critics emphasize the need for swift implementation to avoid long waiting times at clinics. Richard Angell from the Terrence Higgins Trust urged for the injection to be made available in various settings beyond sexual health clinics to reach those currently underserved. He stated, "It's highly effective and acceptable for patients, and a vital tool for tackling inequalities."
Progress Towards Ending HIV Transmission
The rollout of cabotegravir is part of the NHS's broader goal to eliminate new HIV transmissions by 2030. Recent data from the UK Health Security Agency indicates a 4% decrease in new HIV diagnoses from 2023 to 2024, suggesting progress in the fight against the virus. Additionally, the NHS is expanding HIV testing in emergency departments, which is expected to identify nearly 1,900 new or previously missed cases annually.
What's Next
The rollout of cabotegravir is anticipated to begin approximately three months after NICE publishes its final guidance. Health leaders are also exploring the possibility of making PrEP available in primary care settings, such as community pharmacies, to further enhance accessibility and equity in HIV prevention.
Verbatim Quotes
- “Health secretary Wes Streeting said: ‘The approval of this game-changing injection perfectly embodies what this government is determined to deliver – cutting-edge treatments that save lives and leave no one behind.” — Wes Streeting, Secretary of State for Health and Social Care
- “Injectable PrEP will be transformative for our HIV response. It's highly effective and acceptable for patients, and a vital tool for tackling inequalities - with the potential to reach those who are not currently accessing other HIV prevention.” — Richard Angell, Chief Executive of the Terrence Higgins Trust
- “This long-acting injection is a significant addition to our HIV prevention strategies - giving us a powerful new option for people at risk of HIV who cannot have oral PrEP tablets.” — Dr. Michael Brady, National Advisor for LGBT+ Health at NHS England
